Home
Live Updates
Novel Agent Curbs Alzheimers-Related Agitation : vimarsana.com
Novel Agent Curbs Alzheimer's-Related Agitation
AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.
Related Keywords
Pennsylvania ,
United States ,
Mansfield ,
New York ,
University Of Rochester ,
American ,
Antonp Porsteinsson ,
Glenr Finney ,
Rebecca Edelmayer ,
Alzheimer Association ,
Drug Administration ,
American Academy Of Neurology ,
Education Program ,
Disease Care ,
American Academy ,
Cohen Mansfield Agitation Inventory ,
Patient Global Impression ,
Medscape Medical News ,
Geisinger Memory ,
Cognition Clinic ,
Medscape Medical ,
Alzheimer 039s Disease ,
Lzheimer Disease ,
Agitation ,
Antipsychotics ,
Euroleptics ,
Euroleptic Drugs ,
Healthcare And Medical Technology ,
Ealth And Medical Tech ,
Ealth And Med Tech ,
Ealth And Medical Technology ,
Ealthcare Technology ,
Edical Technology ,
Us Food And Drug Administration ,
Nited States Food And Drug Administration ,
Da ,
Patient Safety ,
vimarsana.com © 2020. All Rights Reserved.